Crossmark

Utilizing multi-omics analysis, a new signature has been identified and validated for predicting prognosis and response to immunotherapy in lung squamous cell carcinoma, which is based on tumor mutation burden

Crossref DOI link: https://doi.org/10.1007/s12672-025-02166-2

Published Online: 2025-04-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Dongguang

Wang, Yan

Peng, Yiqun

Peng, Liang
Funding

Funding for this research was provided by:

the Science and Technology Innovation Project of Hunan province (2020SK51601)

the Health Commission of Hunan Province Scientific Research Projects (202203054127)

Loudi Major Scientific and Technological special Project (202201)
License Information

Text and Data Mining valid from 2025-04-16

Version of Record valid from 2025-04-16
More Information

Article History

Received: 30 August 2024

Accepted: 18 March 2025

First Online: 16 April 2025

Declarations

:

: The inclusion of patients' data in TGGA and ICGC databases have been approved by ethical committees. As our study is based on open-source data, the Human Ethics and Consent to Participate declarations were not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below